An enhanced Viradux-AU anti-herpetic cream is now available

Sydney, NSW -- (ReleaseWire) -- 08/21/2013 -- Viradux Research, LTD, announced today that it has developed an improved formulation of its leading anti-herpetic cream Viradux-AU.

Bob Hastings, director of marketing at Viradux Research, LTD announced; "Preliminary observations are suggesting up to 40% improvement in viral responsiveness when compared to the first generation Viradux-AU." This was reportedly achieved by expanding the effectiveness of several key protein inhibitors found in compounds already known to have anti-viral properties. "The combined modality of these well-known elements with our existing delivery system has raised the overall effectiveness. Our original expectation was a fairly modest increase. We are now seeing over 80% of users describing their experience as {completely satisfied with outcome after indicated use}. These preliminary results exceeded our expectations and give us some interesting avenues to pursue."

The reformulated compound began shipping in July of 2013 and is now available through our web sales channel to HSV2 positive individuals, and their partners, whose lives have been impacted by genital herpes. "Our ultimate goal" continued Mr. Hastings "is a product that is able to eradicate all the various types and sub-types of HSV2 infection with 100% effectiveness. While we are not there yet, I am much more confident that the science will get there in the near term. I'm also pleased to announce that there are no expected pricing increases and the 2oz container will remain priced below $30 USD, before shipping, for the near term."

About Viradux
Viradux Research, LTD is a provider of anti-herpetic treatment solutions targeted at the rapid resolution of symptoms related to HSV1 and HSV2 infections. A multi-faceted solution to HSV2 (typically genital) infections is provided in the form of an anti-herpetic topical treatment, marketed globally under the trade-name Viradux-AU™. This solution has also been shown to reduce symptoms, speed healing and prevent future outbreaks in people with moderate to severe HSV2 infections. In 2013, Viradux Research, LTD released to market Viradux-ColdSore™ as the only effective anti-herpetic HSV1 treatment currently available based on type-III epidermal transportation compounds. Viraudx-ColdSore™ lip balm has been shown to speed healing of existing herpetic lesions and prevent the reoccurrence of future outbreaks associated with moderate-to-severe HSV-1 infection.

Further information regarding research results, product information, and viral epidemiology can be found at the company's websites: Viradux Home Page and Viradux-ColdSore Home Page

For more information on this press release visit: http://www.releasewire.com/press-releases/eliminating-genital-herpes-improved-formulation-released-309878.htm

Viradux now shipping world-wide, expanding treatment options for sufferers of HSV1 and HSV2.

Sydney, NSW -- (ReleaseWire) -- 06/11/2013 -- Viradux Research, LTD announced today that it has expanded distribution of Viradux-AU (TM) and Viradux-ColdSore (TM) as the only effective anti-herpetic treatments currently available to consumers based on type-III epidermal transportation compounds.

Viradux-AU anti-herpetic cream and Viraudx-ColdSore lip balm has been shown to speed healing of existing herpetic lesions and prevent the reoccurrence of future outbreaks associated with moderate-to-severe Herpes Simplex Virus (HSV1 and HSV2) infection.

The decision to expand the distribution footprint was based on overwhelming response by the treatment community. Prior to June, shipments were restricted to select US states and certain EU nations. Going forward, the company plans to ship world-wide where not restricted by local governments.

In a statement posted to the Viradux Facebook page, PR Manager Robert Hastings noted; "We have been receiving an avalanche of communications from various sources... e-mail, phone, and of course social media. The message was consistent, when will Viradux products be shipped to my area?"

The posting went on to read; "While our original strategy was based on a more gradual expansion, we feel a certain responsibility to accelerate this plan. We have a very modest advertising effort. The response is primarily being driven by word of mouth. There are perhaps thousands of reports on the internet from people who have described remarkable results from using these products. Others have read these postings and then find out we cannot ship to them, and then let us know how disappointed they are. This will no longer be the case."

Viradux has presented preliminary results indicating that significant improvement (in the form of lesion reduction, and reduction of recurring outbreaks) occurred in roughly 84.7% of participants. This was based on a 2012 study involving a double-blind, placebo-controlled dose escalation clinical trial enrolling approximately 150. Volunteers were selected with moderate-to-severe HSV-1 and HSV-2 infections who were otherwise healthy. The study was designed to evaluate the safety and tolerability of Viradux active components (type-III) and their ability to stimulate the immune system, as well as determine the impact of the compound upon viral shedding, which is considered to be a marker of disease recurrence and transmission. Formal publication of the study is pending.

Viradux Research, LTD
In 2005, A clinical research team at the Royal Melbourne Hospital in cooperation with the virology department of Sydney College made several important discoveries in the field of genomics, cell biology and protein chemistry. These discoveries led to several breakthoughs in the treatment of HSV infection. The decision was made in 2011 to produce and distribute an effective, safe and natural treatment for herpetic viral infections. This product would become Viradux-AU. Further information regarding research results, product information, and viral epidemiology can be found at the company's websites: http://www.viradux.com and http://www.viradux-coldsore.com.

For more information on this press release visit: http://www.releasewire.com/press-releases/could-genital-herpes-become-obsolete-262620.htm

A new partnership agreement in the effort to resolve Herpes HSV1 and HSV2 is announced.

New South Wales, Australia -- (ReleaseWire) -- 04/04/2013 -- Viradux Research, LTD, a provider of anti-herpetic treatment solutions targeted at the rapid resolution of symptoms related to HSV1 and HSV2 infections, announced today that it has reached a joint venture partnership agreement with Benalli of Beijing, China. Benalli is a provider of rapid diagnostic testing solution, cell-based virology assays and molecular diagnostic solutions. Formed to expand and market testing platforms developed at the university of Bejing, in association with the Wuhan Institute of Virology, the company has recently expanded its portfolio of patents to include a new assay for the differentiation and detection of herpes simplex viruses 1 and 2 (HSV 1+2).

"This agreement will benefit both organizations while moving forward the effort to significantly improve the lives of those infected with the herpes simplex virus. Improved testing accuracy and availability are the critical first step in this effort." According to Andrew Bhatnagar of Viradux Research, LTD, "34% of HSV1 infected people are asymptomatic and have no idea that they are unwittingly transmitting this disease. The same is true of roughly 85% of HSV2 carriers. This represents hundreds of millions of individuals world-wide. The fastest way to make a significant impact is through a wide scale, low-cost diagnostic tool that will allow individuals to make informed behavioral and treatment decisions."

Benalli has developed and is seeking approval for a cell-based virology assay that can be deployed in rural conditions. The system includes collection techniques that do not rely on sample refrigeration or time constrained testing procedures. Deployment on a large scale is expected to reduce unit costs to less than $10 USD per test. "Our combined goal is to make available a diagnostic tool that, even when deployed to the most remote locations, will allow an affordable, accurate and rapid diagnosis for the many millions of suffers who are overlooked by the current global health care model." Bhatnager sees this as "an opportunity for Benalli to join forces with the leading edge second generation anti-viral solutions provided by Viradux. The fact is that, while HSV1 and HSV2 site infection are usually oral and genital respectively, configurations can and frequently do occur in reverse, a trend which is becoming more common. Therefore, an accurate test is a critical step in successful treatment. We are of a like mind in that both testing and solutions should be affordable and effective."

Viradux Research, LTD is a provider of a multi-faceted solution to HSV2 (typically genital) infections in the form of an anti-herpetic topical treatment called Viradux-AU™. This solution has also been shown to reduce symptoms, speed healing and prevent future outbreaks in people with moderate to severe HSV2 infections. In 2013, Viradux Research, LTD released to market Viradux-ColdSore™ as the only effective anti-herpetic HSV1 treatment currently available based on type-III epidermal transportation compounds. Viraudx-ColdSore™ lip balm has been shown to speed healing of existing herpetic lesions and prevent the reoccurrence of future outbreaks associated with moderate-to-severe HSV-1 infection.

Further information regarding research results, product information, and viral epidemiology can be found at the company's websites: Viradux Home Page and Viradux-ColdSore Home Page

For more information on this press release visit: http://www.releasewire.com/press-releases/viradux-research-announces-jv-partnership-with-benalli-assays-ltd-232820.htm

Viradux Research now has two options in the war against HSV1 and HSV2.

Sydney, NSW -- (ReleaseWire) -- 03/15/2013 -- Viradux Research, LTD announced today that it has released to market Viradux-ColdSore (TM) as the only effective anti-herpetic HSV1 treatment currently available based on type-III epidermal transportation compounds. Viraudx-ColdSore lip balm has been shown to speed healing of existing herpetic lesions and prevent the reoccurrence of future outbreaks associated with moderate-to-severe Herpes Simplex Virus (HSV-1) infection.

The decision was based on a 2012 study involving a double-blind, placebo-controlled dose escalation clinical trial enrolling approximately 150. Volunteers were selected with moderate-to-severe HSV-1 infections who were otherwise healthy. The study was designed to evaluate the safety and tolerability of Viradux-AU active components (type-III) and their ability to stimulate the immune system, as well as determine the impact of the compound upon viral shedding, which is considered to be a marker of disease recurrence and transmission.

Viradux also provides a solution to HSV2 (genital) infections in the form of an anti-herpetic creme called Viradux-AU. This has also been shown to reduce symptoms, speed healing and prevent future outbreaks in people with moderate to severe HSV2 infections.

"This work provided proof-of-concept that our specific delivery vehicles are successful in topical, localized therapeutics in the fight against herpes" postdoctoral researcher Alysia Kenburogh said in an October interview in Nature. Kenborogh, the lead author of the paper, went on to describe the viral mortality rates as "unexpectedly high and outside our original estimates". Upon learning that this research had led to the decision to market the product Kenburogh admitted that she felt "proud to know something that was originally pure research with no financial goals had resulted in a new product. Mostly, I am pleased that the HSV positive population will have access to a new and more effective treatment option for this unpleasant infection."

Further information regarding research results, product information, and viral epidemiology can be found at the company's websites: http://www.viradux.com and http://www.viradux-coldsore.com.

Viradux Website

Viradux ColdSore Website

For more information on this press release visit: http://www.releasewire.com/press-releases/new-options-in-herpes-treatments-222397.htm